FMA
ELDN icon

FNY Managed Accounts’s Eledon Pharmaceuticals ELDN Stock Holding History

FNY Managed Accounts’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-40
Closed -$36.1K – 331
2016
Q1 		$36.1K Buy
+40
New +$39.3K 0.06% 160

Other funds holding ELDN

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

FNY Managed Accounts's ELDN Position: Q2 2016 in Review

FNY Managed Accounts sold out of Eledon Pharmaceuticals (ELDN) in Q2 2016, closing a stake of 40 shares — an estimated $36.1K sold.

FNY Managed Accounts first reported a position in ELDN in Q1 2016 and held it in 1 quarter. The position peaked at $36.1K in Q1 2016. 48 funds tracked by Wall St. Rank hold ELDN as of Q2 2016.

  • FNY Managed Accounts reported no remaining Eledon Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 40 Eledon Pharmaceuticals shares in Q2 2016, an estimated $36.1K.
  • FNY Managed Accounts first reported a position in Eledon Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Eledon Pharmaceuticals position peaked at $36.1K in Q1 2016.
  • 48 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2016.

Based on FNY Managed Accounts's 13F filing for Q2 2016, filed 27 Jul 2016.